Pharmaceuticals | Can you leverage from a purchase price allocation for transfer pricing purposes?
Channel: MyTPAGlobal
Date: 2013-11-29

A considerable amount of discussion is generated regarding the implications of a purchase price allocation for transfer pricing purposes. As such this third web event will address the following question: Can you leverage from a purchase price allocation for transfer pricing purposes? 
Following an acquisition the purchase price paid must be allocated to all identifiable assets and liabilities assumed, following a set of accounting rules outlined within IFRS 3 and IAS 38. Does the identification criteria outlined in IAS 38 meet the definition of intangibles for transfer pricing purposes? What is really included in the "left over" that is usually referred to as "goodwill" and how valuable can this "goodwill" be for pharmaceutical companies? Is it possible to bridge the gap between PPAs based on accounting rules versus tax/transfer pricing treatment and mitigate the effect on the future transfer pricing model that will result from the accounting treatment of goodwill? How to manage the risk of running a high effective tax rates?

The web event will address the following:

- Overview of the reporting rules currently in place;
- How to bridge the gap between PPAs for reporting purposes versus the relevant tax/transfer pricing treatment, what are the similarities and differences;
- How important is "goodwill" for pharmaceutical companies.

At the end of the web event, you will:

- Recognize to what extent acquisition accounting for financial reporting purposes can be used for tax/transfer pricing purposes;
- How to mitigate the effect on the future transfer pricing model that will result from the accounting treatment of goodwill.

Speaker(s):

- Yariv Ben-Dov, Founding Partner, Bar-Zvi & Ben-Dov Law Offices 
Yariv Ben-Dov is the founding partner of Bar-Zvi & Ben-Dov Law Offices. Yariv has successfully managed transfer pricing assessments and tax due diligence for M&A, transfer pricing planning, documentation, and audits, all over the globe, for a number of international conglomerates in various fields of industries. 
http://http://www.bbl.co.il

- Igor Soroka, Senior Manager, Richter
Igor Soroka is a Senior Manager who has worked in the Transfer Pricing field since 2006. Igor has been involved in preparing transfer pricing documentation and providing audit defense support to various clients in Pharmaceutical, Apparel, Information Technology and other industries. 
http://www.richter.ca

- Ioanna Ninou, Associate, Transfer Pricing Associates
Ioanna Ninou graduated from the Rotterdam School of Management Erasmus University and is a valuation and transfer pricing specialist at Transfer Pricing Associates. 
http://www.tpa-global.com